Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HRH1 | P35367 | 2/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.39 |
| ▸ | NAAA | Q02083 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24220982 | 0.90 | FOLH1 (0.44) | TLR2NPSR1MMETSHRFOLH1 | |
| SCHEMBL21081697 | 0.89 | MME (0.43) | TLR2NPSR1MMETSHRFOLH1 | |
| SCHEMBL23052535 | 0.89 | MME (0.43) | TLR2NPSR1MMETSHRFOLH1 | |
| SCHEMBL21081698 | 0.88 | HTR2A (0.47) | HTR2AHRH1NPSR1MMETSHR | |
| SCHEMBL21081675 | 0.88 | HTR2A (0.47) | HTR2AHRH1NPSR1MMETSHR | |
| SCHEMBL24677893 | 0.88 | NPSR1 (0.45) | TLR2NPSR1MMEFOLH1NAAA | |
| SCHEMBL21736741 | 0.86 | HTR2A (0.45) | HTR2AHRH1TLR2NPSR1MME | |
| SCHEMBL21787357 | 0.85 | HTR2A (0.44) | HTR2AHRH1NPSR1MMETSHR | |
| SCHEMBL24677821 | 0.84 | HTR2A (0.41) | HTR2AHRH1NPSR1MMETSHR | |
| SCHEMBL21081699 | 0.84 | HTR2A (0.41) | HTR2AHRH1NPSR1MMETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220273807-A1 | CONJUGATES FOR USE IN METHODS OF TREATING CANCER | ASTRAZENECA AB (SE) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273807-A1 | CONJUGATES FOR USE IN METHODS OF TREATING CANCER | CD44, FOLH1, SLC17A5 | HTR2A 4024/4885HRH1 3040/4885TLR2 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.